Correlative Studies with Specimens from Multi-Site Trials (R21)

The summary for the Correlative Studies with Specimens from Multi-Site Trials (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Correlative Studies with Specimens from Multi-Site Trials (R21): -Purpose. This Funding Opportunity Announcement (FOA) is intended to support translational correlative studies that utilize annotated tumor and/or other biospecimens collected during large-scale multi-institutional clinical and/or prevention trials, respectively. The Cancer Therapy Evaluation Program (CTEP), the Cancer Diagnosis Program (CDP), and the Cancer Biomarkers Research Group (CBRG) of the NCI are cooperatively sponsoring this FOA with the overarching goal to facilitate predictions of responses to current interventions, and inspire future development of improved therapeutic and preventive strategies. Projects proposed in response to this FOA should address the correlations between intervention outcomes and cancer patients' disease characteristics determined at various cellular/molecular levels. For example, disease progression patterns may be correlated with tumor genotypic and/or phenotypic profiles (at the levels of the genome, epigenome, gene expression and/or protein and non-protein molecular markers. This FOA will only support studies that use tumor specimens linked to specific interventions/trials. To be able to achieve these translational goals, the proposed projects are expected to rely on interactions between basic researchers and clinical investigators, in order to improve future drug development and interventions. -Mechanism of Support. This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-134, that solicits applications under the NIH Research Project Grant (R01) mechanism.
Federal Grant Title: Correlative Studies with Specimens from Multi-Site Trials (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-08-133
Type of Funding: Grant
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: May 07, 2011
Original Application Deadline: May 07, 2011
Posted Date: Apr 04, 2008
Creation Date: Dec 05, 2008
Archive Date: Jun 07, 2011
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government Non-domestic (non-U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com